key: cord-0997870-004mn003
authors: Li, Yaning; Fan, Qing; Zhou, Bing; Shen, Yaping; Zhang, Yuanyuan; Cheng, Lin; Qi, Furong; Song, Shuo; Guo, Yingying; Yan, Renhong; Ju, Bin; Zhang, Zheng
title: Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants
date: 2022-05-18
journal: iScience
DOI: 10.1016/j.isci.2022.104431
sha: 23b41a7a660a4fb8ecf99cb197dbf9d6e214fced
doc_id: 997870
cord_uid: 004mn003

The different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have attracted most public concern because they caused “wave and wave” COVID-19 pandemic. The initial step of viral infection is mediated by the SARS-CoV-2 Spike (S) protein, which mediates the receptor recognition and membrane fusion between virus and host cells. Neutralizing antibodies (nAbs) targeting the S protein of SARS-CoV-2 have become promising candidates for clinical intervention strategy, while multiple studies have shown that different variants have enhanced infectivity and antibody resistance. Here, we explore the structure and function of STS165, a broadly inter-Spike bivalent nAb against SARS-CoV-2 variants and even SARS-CoV, contributing to further understanding of the working mechanism of nAbs.

The different variants of severe acute respiratory syndrome coronavirus 2 26 (SARS-CoV-2) have attracted most public concern because they caused "wave Omicron variant is a new variant of concern (VOC) identified in South Africa since 46 November 2021 and has spread rapidly across the world. 47 One of the reasons for the prevalence of Omicron variant is that over 30 mutations 48 occur in the Spike protein on the virion surface, which is responsible for receptor 49 recognition. During viral infection, the trimeric S protein binds to the host receptor 50 and is cleaved into S1 and S2 subunits by host protease (Belouzard et Alpha, Beta, Gamma, Delta, Lambda, Mu, Kappa, Eta, Epsilon, Iota, C.1.2, and even 83 Omicron, indicating its great potential. Especially, STS165 also neutralizes 84 SARS-CoV with 50% inhibitory concentration (IC50) of 2.087 μg/mL ( Figure 1A ).

Relatively high binding affinities to RBD proteins of SARS-CoV-2 variants and 86 SARS-CoV in the nanomolar range or below contributed to the broadly neutralizing 87 activities of STS165 ( Figure S1 ). Although the binding affinity of STS165 to Omicron 88 RBD was simply decreased by 3-fold than that to WT RBD, its neutralizing activity 89 was largely reduced by these mutations. Similar results were also observed in the 90 binding and neutralizing activities of the other two nAbs, AZD8895 and AZD1061 91 (Cao et al., 2021) , suggesting that the monomeric RBD protein could not fully 92 represent the native conformational Spike trimer on the surface of virus membrane to 93 evaluate the interaction between nAbs and virus, especially the neutralization. These 94 data indicated that STS165 maintained the neutralization activity against Omicron and 95 even SARS-CoV despite the significant reduction. These data also suggest that there 96 are many key binding sites between STS165 and Omicron that deserve further 97 exploration.

It is widely known that RBD-specific nAbs could be divided into four classes 99 according to the competition with ACE2 and the accessibility of epitopes recognized ACE2. STS165 exhibited high capacity in competing with ACE2 receptor, which is 103 similar to the representative Class 1 antibody P2C-1F11 and Class 2 antibody 104 BD-368-2 ( Figure 1B, left panel) . To identify a more precise epitope recognized by 105 STS165, we further measured its competition with other 14 monoclonal antibodies indicating that STS165 belongs to the Class 4 antibody whose recognition site was far 113 away from the receptor-binding motif (RBM).

Many diverse SARS-CoV-2 variants have emerged and spread around the world.

These variants are resistant to specific monoclonal antibodies that have been 116 authorized or approved for clinical use. Especially, the Omicron has escaped most of 117 the authorized nAbs except S309 (Cao et al., 2021) . Thus, it is urgent to rescue the 118 lost neutralization of these nAbs against Omicron and ongoing variants. As STS165 119 can neutralize 13 variants including Beta, Delta, and Omicron, it may be an ideal 120 partner to form a therapeutic antibody cocktail. This cocktail is not only an effective 121 treatment but may also protect against antibody resistance caused by virus escape 122 mutants that could arise in response to selective pressure from single antibody 123 treatments. We evaluated the escape of the 11 pseudoviruses from neutralization by 124 J o u r n a l P r e -p r o o f the STS165 in combination with other 3 non-competition nAbs approved for clinical 125 use (REGN10933, REGN10987, and S309). As shown in Figure 1C and Figure S2 , 126 the level of REGN10933 against Beta was lower than that against WT, displaying a 127 significant decrease in IC50 (2.318 μg/mL). Importantly, the inhibition values of 128 REGN10933 and REGN10987 against Omicron and SARS-CoV were below 50% 129 when tested at the highest concentration (50 μg/mL). However, the approved 130 antibodies REGN10933 and REGN10987 in combination with STS165, respectively, 131 restored their neutralizing activities against Omicron and SARS-CoV to some extent.

Notably, for other variants, STS165 cocktail therapy with REGN10933, REGN10987, 133 and S309 antibodies, respectively, also maintained their neutralizing activities against 134 pseudoviruses. In summary, these results indicate that STS165 is not only a broadly Table S1 ) (Cui et al., 2022) . The excess antibodies ( Figure S6A ). The peak fractions containing the complex were 147 concentrated for further cryo-EM sample preparation.

The cryo-EM structure of Omicron S-6p bound with STS165 was determined at an 149 overall resolution of 3.3 Å (Figure 2A , Figures S5-S7 , and Table S1 ). However, the 150 resolution at the interface between RBD and STS165 was not high enough to reveal a 151 detailed interaction network due to the flexibility of this region even with focused 152 refinement applied. To characterize the putative epitope, we docked an Alphafold 153 predicted STS165 into the density for analysis. When aligned with the ACE2-binding 154 site on the RBD, we can find the overlap between ACE2 and STS165, consistent with 155 our competition assays ( Figure 2B ).

The STS165 binding Omicron S-6p exhibits a conformation with three "up" RBDs, be classified into Class 4, which also includes H014, EY6A, and S304 ( Figure 2C ). 161 We mapped the epitope of STS165 on the RBD of Omicron variant and found that the Intriguingly, we found a special binding pattern of STS165 in our 2D classification, of 172 which the "head to head Spike" is revealed for the first time ( Figure 2F ). This pattern Compared with the IgG form ( Figure S1 ), the binding affinity of STS165-Fab to WT 188 or Omicron RBD was largely decreased by more than 50-fold, which was partially 189 responsible for the serious reduction in neutralizing activity.

The COVID-19 pandemic has lasted for more than two years around the world (Zhou 193 et al., 2020b). As a variety of variants continue to appear, SARS-CoV-2 largely with secondary structure and geometry restraints to prevent overfitting. To monitor 469 the potential overfitting, the model was refined against one of the two independent 470 half maps from the gold-standard 3D refinement approach. Then, the refined model 471 was tested against the other map. Statistics associated with data collection, 3D 472 reconstruction and model building were summarized in Table S1 . 

PHENIX: a comprehensive Python-based system 485 for macromolecular structure solution

SARS-CoV-2 neutralizing antibody 489 structures inform therapeutic strategies

Activation of the SARS coronavirus spike 491 protein via sequential proteolytic cleavage at two distinct sites

Broadly neutralizing antibodies overcome SARS-CoV

Omicron antigenic shift

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

High-resolution noise substitution to measure overfitting and validate resolution in 3D 500 structure determination by single particle electron cryomicroscopy

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited 503 serum and monoclonal antibodies

Structural and functional characterizations of altered infectivity and immune evasion of 506 SARS-CoV-2 Omicron variant

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread 509 escape from neutralizing antibody responses

Antibody evasion by the P.1 strain of 512 SARS-CoV-2

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters 515 and Provides a Potent Cocktail Pairing Strategy

Potent dengue virus neutralization by a 518 therapeutic antibody with low monovalent affinity requires bivalent engagement

Features and development of Coot

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

Host cell proteases: Critical determinants of coronavirus 560 tropism and pathogenesis

Mapping Neutralizing and Immunodominant 563 Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution

Cross-neutralization of SARS-CoV-2 by a human monoclonal 567 SARS-CoV antibody

Reduced sensitivity of SARS-CoV-2 variant Delta to 570 antibody neutralization

cryoSPARC: algorithms for rapid 572 unsupervised cryo-EM structure determination

Optimal determination of particle orientation, absolute 574 hand, and contrast loss in single-particle electron cryomicroscopy

A Bayesian view on cryo-EM structure determination

RELION: implementation of a Bayesian approach to cryo-EM structure 579 determination

A 581 human neutralizing antibody targets the receptor binding site of SARS-CoV-2

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike 587 glycoprotein-mediated viral entry

Proteolytic activation of 589 the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research

spike glycoprotein in complex with its host cell receptor ACE2

Flexible fitting of atomic 594 structures into electron microscopy maps using molecular dynamics

Antibody Resistance of SARS-CoV-2 Variants B

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human 600 potent neutralizing antibodies

Structural basis for the recognition of 602 the SARS-CoV-2 by full-length human ACE2

Structural and functional ramifications of antigenic drift in recent 605 SARS-CoV-2 variants

Gctf: Real-time CTF determination and correction

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron 609 microscopy

Structural basis for the neutralization of SARS-CoV-2 by 612 an antibody from a convalescent patient

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

New tools for automated high-resolution cryo-EM structure

using a 2.6 A reconstruction of rotavirus VP6. eLife 4, e06980. 527Hansen, J., Baum, A., Pascal, K.E., Russo, V., Giordano, S., Wloga, E., Fulton, B.O., Yan, Y., Koon, K., 528 Patel, K., et al. (2020) . Studies in humanized mice and convalescent humans yield a SARS-CoV-2 529 antibody cocktail. Science.